Alto Neuroscience, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ANRO New York 2834 www.altoneuroscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alto Neuroscience, Inc.

Metagenomi Leads The Charge With These 3 Penny Stocks - Apr 8th, 2025 5:05 pm
Alto Neuroscience initiated with a Buy at H.C. Wainwright - Apr 8th, 2025 2:15 pm
Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights - Mar 20th, 2025 8:10 pm
Christopher Nixon Cox Named Chairman of High-Trend International Group - Mar 13th, 2025 1:00 pm
Jefferies Predicts Up to ~500% Jump for These 2 ‘Strong Buy’ Stocks - Mar 2nd, 2025 11:15 am
Alto Neuroscience to Participate in Upcoming Investor Conferences - Feb 25th, 2025 1:03 pm
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker - Feb 19th, 2025 1:03 pm
Promising US Penny Stocks To Watch In February 2025 - Feb 18th, 2025 8:11 pm
Pleasing Signs As A Number Of Insiders Buy Alto Neuroscience Stock - Feb 18th, 2025 1:48 pm
Alto Neuroscience reports positive outcomes from Phase IIb trial of MDD therapy - Feb 13th, 2025 10:01 am
Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial - Feb 12th, 2025 1:03 pm
All You Need to Know About Alto Neuroscience, Inc. (ANRO) Rating Upgrade to Buy - Jan 8th, 2025 5:00 pm
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology - Dec 11th, 2024 1:03 pm
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Nov 12th, 2024 9:10 pm
Wedbush downgrades Alto Neuroscience to Neutral following ALTO-100 readout - Oct 24th, 2024 12:32 pm
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform - Oct 23rd, 2024 5:36 pm
Alto hits new low as depression drug flunks key test - Oct 23rd, 2024 12:03 pm
Alto’s Phase IIb study of ALTO-100 for MDD fails to meet primary endpoint - Oct 23rd, 2024 11:32 am
Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder - Oct 22nd, 2024 8:30 pm
Alto Neuroscience Insiders Placed Bullish Bets Worth US$638.5k - Sep 11th, 2024 1:08 pm